{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T05:24:00Z","timestamp":1794201840312,"version":"4.8.0"},"reference-count":167,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1053\/j.seminhematol.2024.10.001","type":"journal-article","created":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T02:36:04Z","timestamp":1728095764000},"page":"20-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["The role of 1q abnormalities in multiple myeloma: Genomic insights, clinical implications, and therapeutic challenges"],"prefix":"10.1053","volume":"62","author":[{"given":"Zachary M.","family":"Avigan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine S.","family":"Mitsiades","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1134-0564","authenticated-orcid":false,"given":"Alessandro","family":"Lagan\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1053\/j.seminhematol.2024.10.001_bib0001","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.10.001_bib0002","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.10.001_bib0003","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-020-00359-2","article-title":"Multiple myeloma current treatment algorithms","volume":"10","author":"Rajkumar","year":"2020","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.10.001_bib0004","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/leu.2013.247","article-title":"IMWG consensus on risk stratification in multiple myeloma","volume":"28","author":"Chng","year":"2014","journal-title":"Leukemia"},{"issue":"24","key":"10.1053\/j.seminhematol.2024.10.001_bib0005","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.10.001_bib0006","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41571-018-0018-y","article-title":"The multiple myelomas - current concepts in cytogenetic classification and therapy","volume":"15","author":"Kumar","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.10.001_bib0007","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1158\/0008-5472.CAN-17-3115","article-title":"From MGUS to multiple myeloma, a paradigm for clonal evolution of premalignant cells","volume":"78","author":"van Nieuwenhuijzen","year":"2018","journal-title":"Cancer Res"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.10.001_bib0008","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1182\/bloodadvances.2019000779","article-title":"Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma","volume":"4","author":"Ziccheddu","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.10.001_bib0009","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0165-4608(94)00284-I","article-title":"Cytogenetic findings in 200 patients with multiple myeloma","volume":"82","author":"Sawyer","year":"1995","journal-title":"Cancer Genet Cytogenet"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.10.001_bib0010","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood-2006-03-009910","article-title":"Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation","volume":"108","author":"Hanamura","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.10.001_bib0011","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41408-024-00985-0","article-title":"Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review","volume":"14","author":"Neupane","year":"2024","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.10.001_bib0012","doi-asserted-by":"crossref","first-page":"e1169","DOI":"10.1200\/JOP.19.00639","article-title":"Variability in cytogenetic testing for multiple myeloma: a comprehensive analysis from across the United States","volume":"16","author":"Yu","year":"2020","journal-title":"JCO Oncol Pract"},{"issue":"26","key":"10.1053\/j.seminhematol.2024.10.001_bib0013","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"29","key":"10.1053\/j.seminhematol.2024.10.001_bib0014","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project","volume":"40","author":"D'Agostino","year":"2022","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.10.001_bib0015","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41408-019-0226-4","article-title":"An acquired high-risk chromosome instability phenotype in multiple myeloma: jumping 1q Syndrome","volume":"9","author":"Sawyer","year":"2019","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.10.001_bib0016","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/gcc.20109","article-title":"Genomic instability in multiple myeloma: evidence for jumping segmental duplications of chromosome arm 1q","volume":"42","author":"Sawyer","year":"2005","journal-title":"Genes Chromosomes Cancer"},{"issue":"16","key":"10.1053\/j.seminhematol.2024.10.001_bib0017","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1182\/blood-2013-12-546077","article-title":"Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease","volume":"123","author":"Sawyer","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.10.001_bib0018","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1038\/s41467-019-11680-1","article-title":"Genomic landscape and chronological reconstruction of driver events in multiple myeloma","volume":"10","author":"Maura","year":"2019","journal-title":"Nat Commun"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.10.001_bib0019","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1182\/blood-2023-182267","article-title":"The temporal evolution of chromosome 1q gain and hyperdiploidy and its impact on clinical outcomes in multiple myeloma","volume":"142","author":"Maura","year":"2023","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.10.001_bib0020","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","article-title":"A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1","volume":"109","author":"Shaughnessy","year":"2007","journal-title":"Blood"},{"issue":"29","key":"10.1053\/j.seminhematol.2024.10.001_bib0021","doi-asserted-by":"crossref","first-page":"4798","DOI":"10.1200\/JCO.2007.13.8545","article-title":"Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du My\u00e9lome","volume":"26","author":"Decaux","year":"2008","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.10.001_bib0022","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41588-024-01853-0","article-title":"Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes","volume":"56","author":"Skerget","year":"2024","journal-title":"Nat Genet"},{"issue":"47","key":"10.1053\/j.seminhematol.2024.10.001_bib0023","doi-asserted-by":"crossref","first-page":"eabg9551","DOI":"10.1126\/sciadv.abg9551","article-title":"Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications","volume":"7","author":"Bhalla","year":"2021","journal-title":"Sci Adv"},{"issue":"24","key":"10.1053\/j.seminhematol.2024.10.001_bib0024","doi-asserted-by":"crossref","first-page":"7776","DOI":"10.1158\/1078-0432.CCR-11-1791","article-title":"Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival","volume":"17","author":"Boyd","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.10.001_bib0025","doi-asserted-by":"crossref","first-page":"4995","DOI":"10.1182\/blood-2006-07-038703","article-title":"CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms","volume":"109","author":"Zhan","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.10.001_bib0026","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3324\/haematol.2023.283200","article-title":"Identification of PSMB4 and PSMD4 as novel target genes correlated with 1q21 amplification in patients with smoldering myeloma and multiple myeloma","volume":"109","author":"Garcia","year":"2024","journal-title":"Haematologica"},{"issue":"21","key":"10.1053\/j.seminhematol.2024.10.001_bib0027","first-page":"2599","article-title":"Ubiquitin receptor PSMD4\/Rpn10 is a novel therapeutic target in multiple myeloma","volume":"141","author":"Du","year":"2023","journal-title":"Blood"},{"issue":"19","key":"10.1053\/j.seminhematol.2024.10.001_bib0028","doi-asserted-by":"crossref","first-page":"7577","DOI":"10.1158\/0008-5472.CAN-09-0773","article-title":"BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells","volume":"69","author":"Mani","year":"2009","journal-title":"Cancer Res"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.10.001_bib0029","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1006\/cbir.2000.0497","article-title":"Role of INTERLEUKIN-6 in the pathogenesis of multiple myeloma","volume":"24","author":"Gad\u00f3","year":"2000","journal-title":"Cell Biol Int"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.10.001_bib0030","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.3324\/haematol.2019.221176","article-title":"IL6R-STAT3-ADAR1 (P150) interplay promotes oncogenicity in multiple myeloma with 1q21 amplification","volume":"105","author":"Teoh","year":"2020","journal-title":"Haematologica"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.10.001_bib0031","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1182\/blood.V99.6.1885","article-title":"Myeloid cell factor-1 is a critical survival factor for multiple myeloma","volume":"99","author":"Zhang","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.10.001_bib0032","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.699629","article-title":"Mcl-1 inhibition: managing malignancy in multiple myeloma","volume":"12","author":"Al-Odat","year":"2021","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.10.001_bib0033","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1158\/1535-7163.MCT-15-0730","article-title":"Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist Venetoclax in multiple myeloma models","volume":"15","author":"Punnoose","year":"2016","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.10.001_bib0034","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/ni.2527","article-title":"Mcl-1 is essential for the survival of plasma cells","volume":"14","author":"Peperzak","year":"2013","journal-title":"Nat Immunol"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.10.001_bib0035","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/blood.V100.1.194","article-title":"Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells","volume":"100","author":"Derenne","year":"2002","journal-title":"Blood"},{"issue":"24","key":"10.1053\/j.seminhematol.2024.10.001_bib0036","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1182\/bloodadvances.2019000702","article-title":"Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting","volume":"3","author":"Slomp","year":"2019","journal-title":"Blood Adv"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.10.001_bib0037","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1038\/s41467-017-01890-w","article-title":"Alu-dependent RNA editing of GLI1 promotes malignant regeneration in multiple myeloma","volume":"8","author":"Lazzari","year":"2017","journal-title":"Nat Commun"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.10.001_bib0038","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1182\/blood-2018-02-832576","article-title":"Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis","volume":"132","author":"Teoh","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.10.001_bib0039","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ccell.2017.05.011","article-title":"ILF2 Is a regulator of RNA splicing and DNA damage response in 1q21-amplified multiple myeloma","volume":"32","author":"Marchesini","year":"2017","journal-title":"Cancer Cell"},{"issue":"13","key":"10.1053\/j.seminhematol.2024.10.001_bib0040","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1182\/blood.2021014391","article-title":"Systems medicine dissection of chr1q-amp reveals a novel PBX1-FOXM1 axis for targeted therapy in multiple myeloma","volume":"139","author":"Trasanidis","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.10.001_bib0041","doi-asserted-by":"crossref","first-page":"774","DOI":"10.3324\/haematol.2019.222133","article-title":"The hydroxymethylome of multiple myeloma identifies FAM72D as a 1q21 marker linked to proliferation","volume":"105","author":"Chatonnet","year":"2020","journal-title":"Haematologica"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.10.001_bib0042","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3390\/biom13071139","article-title":"The role of S100A6 in human diseases: molecular mechanisms and therapeutic potential","volume":"13","author":"Yang","year":"2023","journal-title":"Biomolecules"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.10.001_bib0043","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1073\/pnas.0508476103","article-title":"Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo","volume":"103","author":"Francoz","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.10.001_bib0044","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3892\/mmr.2022.12791","article-title":"ANP32E contributes to gastric cancer progression via NUF2 upregulation","volume":"26","author":"Zhu","year":"2022","journal-title":"Mol Med Rep"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.10.001_bib0045","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1186\/s12885-020-07556-z","article-title":"Over-expression of ANP32E is associated with poor prognosis of pancreatic cancer and promotes cell proliferation and migration through regulating \u03b2-catenin","volume":"20","author":"Zhang","year":"2020","journal-title":"BMC Cancer"},{"issue":"19","key":"10.1053\/j.seminhematol.2024.10.001_bib0046","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1182\/blood.2023019758","article-title":"Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysis","volume":"142","author":"Poos","year":"2023","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.10.001_bib0047","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1038\/s41375-022-01597-y","article-title":"Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence","volume":"36","author":"Misund","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.10.001_bib0048","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1038\/s41467-022-32145-y","article-title":"The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states","volume":"13","author":"Rasche","year":"2022","journal-title":"Nat Commun"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.10.001_bib0049","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/leu.2013.86","article-title":"Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma","volume":"27","author":"Rajkumar","year":"2013","journal-title":"Leukemia"},{"issue":"21","key":"10.1053\/j.seminhematol.2024.10.001_bib0050","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.20.00437","article-title":"Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression","volume":"38","author":"Bustoros","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.10.001_bib0051","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.3324\/haematol.2017.163766","article-title":"The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma","volume":"102","author":"Mikulasova","year":"2017","journal-title":"Haematologica"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.10.001_bib0052","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","article-title":"Genomic complexity of multiple myeloma and its clinical implications","volume":"14","author":"Manier","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.10.001_bib0053","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41408-019-0199-3","article-title":"Deciphering the chronology of copy number alterations in Multiple Myeloma","volume":"9","author":"Aktas Samur","year":"2019","journal-title":"Blood Cancer J"},{"issue":"34","key":"10.1053\/j.seminhematol.2024.10.001_bib0054","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1200\/JCO.2012.48.4923","article-title":"Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load","volume":"31","author":"Neben","year":"2013","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.10.001_bib0055","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1038\/leu.2012.128","article-title":"SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status","volume":"26","author":"L\u00f3pez-Corral","year":"2012","journal-title":"Leukemia"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.10.001_bib0056","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1038\/s41375-019-0634-2","article-title":"Cytogenetic subclone formation and evolution in progressive smoldering multiple myeloma","volume":"34","author":"Merz","year":"2020","journal-title":"Leukemia"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.10.001_bib0057","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","article-title":"Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.10.001_bib0058","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-024-01053-3","article-title":"The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression","volume":"14","author":"Medina-Herrera","year":"2024","journal-title":"Blood Cancer J"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.10.001_bib0059","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1158\/1078-0432.CCR-10-1066","article-title":"The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells","volume":"17","author":"L\u00f3pez-Corral","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.10.001_bib0060","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1182\/blood-2013-07-515239","article-title":"Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120)","volume":"123","author":"Dhodapkar","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.10.001_bib0061","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1038\/s41375-020-01096-y","article-title":"Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the myeloma XI trial","volume":"35","author":"Croft","year":"2021","journal-title":"Leukemia"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.10.001_bib0062","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1038\/s41375-018-0153-6","article-title":"Multiple myeloma clonal evolution in homogeneously treated patients","volume":"32","author":"Corre","year":"2018","journal-title":"Leukemia"},{"issue":"25","key":"10.1053\/j.seminhematol.2024.10.001_bib0063","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma","volume":"40","author":"Costa","year":"2022","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.10.001_bib0064","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1182\/blood.2023022080","article-title":"Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma","volume":"143","author":"D'Agostino","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.10.001_bib0065","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1038\/s41467-024-48327-9","article-title":"1q amplification and PHF19 expressing high-risk cells are associated with relapsed\/refractory multiple myeloma","volume":"15","author":"Johnson","year":"2024","journal-title":"Nat Commun"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.10.001_bib0066","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1182\/blood.2022017010","article-title":"Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed\/refractory myeloma","volume":"141","author":"Ansari-Pour","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.10.001_bib0067","doi-asserted-by":"crossref","first-page":"6960","DOI":"10.1038\/s41467-021-26951-z","article-title":"Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics","volume":"12","author":"Tirier","year":"2021","journal-title":"Nat Commun"},{"issue":"13","key":"10.1053\/j.seminhematol.2024.10.001_bib0068","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1182\/blood-2016-06-723007","article-title":"Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma","volume":"128","author":"Weinhold","year":"2016","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.10.001_bib0069","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1200\/JCO.21.01987","article-title":"Multiple myeloma, high-risk secondary genetic events observed at relapse are present from diagnosis in tiny, undetectable subclonal populations","volume":"41","author":"Lannes","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.10.001_bib0070","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/s41375-024-02237-3","article-title":"Fluorescence in situ hybridization reveals the evolutionary biology of minor clone of gain\/amp(1q) in multiple myeloma","volume":"38","author":"Cui","year":"2024","journal-title":"Leukemia"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.10.001_bib0071","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","article-title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group","volume":"9","author":"Raje","year":"2022","journal-title":"Lancet Haematol"},{"issue":"13","key":"10.1053\/j.seminhematol.2024.10.001_bib0072","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.3390\/cancers13133213","article-title":"Mechanisms of immune evasion in multiple myeloma: open questions and therapeutic opportunities","volume":"13","author":"Botta","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.10.001_bib0073","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1007\/s12185-023-03579-x","article-title":"Immune dysregulation in multiple myeloma: the current and future role of cell-based immunotherapy","volume":"117","author":"Russell","year":"2023","journal-title":"Int J Hematol"},{"key":"10.1053\/j.seminhematol.2024.10.001_bib0074","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1027385","article-title":"Immunotherapy for the treatment of multiple myeloma","volume":"13","author":"Boussi","year":"2022","journal-title":"Front Immunol"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.10.001_bib0075","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/MOH.0000000000000259","article-title":"Ghobrial IM. Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma","volume":"23","author":"Manier","year":"2016","journal-title":"Curr Opin Hematol"},{"key":"10.1053\/j.seminhematol.2024.10.001_bib0076","doi-asserted-by":"crossref","first-page":"636","DOI":"10.3389\/fonc.2020.00636","article-title":"Deregulation of adaptive T cell immunity in multiple myeloma: insights into mechanisms and therapeutic opportunities","volume":"10","author":"Leblay","year":"2020","journal-title":"Front Oncol"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.10.001_bib0077","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1080\/10428194.2020.1751840","article-title":"Low absolute CD4(+) T cell counts in peripheral blood predict poor prognosis in patients with newly diagnosed multiple myeloma","volume":"61","author":"Gu","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.10.001_bib0078","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/iid3.53","article-title":"The proportion of CD16(+)CD14(dim) monocytes increases with tumor cell load in bone marrow of patients with multiple myeloma","volume":"3","author":"Sponaas","year":"2015","journal-title":"Immun Inflamm Dis"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.10.001_bib0079","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3324\/haematol.2016.153841","article-title":"IL21R expressing CD14(+)CD16(+) monocytes expand in multiple myeloma patients leading to increased osteoclasts","volume":"102","author":"Bolzoni","year":"2017","journal-title":"Haematologica"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.10.001_bib0080","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3324\/haematol.2012.067272","article-title":"Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry","volume":"98","author":"Pessoa de Magalh\u00e3es","year":"2013","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2024.10.001_bib0081","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.3389\/fimmu.2018.01492","article-title":"V\u03b39V\u03b42 T cells in the bone marrow of myeloma patients: a paradigm of microenvironment-induced immune suppression","volume":"9","author":"Castella","year":"2018","journal-title":"Front Immunol"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.10.001_bib0082","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","article-title":"Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma","volume":"1","author":"Zavidij","year":"2020","journal-title":"Nat Cancer"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.10.001_bib0083","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.1002\/cam4.1596","article-title":"ARNT\/HIF-1\u03b2 links high-risk 1q21 gain and microenvironmental hypoxia to drug resistance and poor prognosis in multiple myeloma","volume":"7","author":"Wu","year":"2018","journal-title":"Cancer Med"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.10.001_bib0084","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/leu.2011.204","article-title":"A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial","volume":"26","author":"Boyd","year":"2012","journal-title":"Leukemia"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.10.001_bib0085","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1182\/blood-2011-09-379164","article-title":"Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p","volume":"119","author":"Neben","year":"2012","journal-title":"Blood"},{"issue":"16","key":"10.1053\/j.seminhematol.2024.10.001_bib0086","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1200\/JCO.2011.36.5726","article-title":"Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival","volume":"30","author":"Avet-Loiseau","year":"2012","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.10.001_bib0087","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1182\/blood-2014-07-584268","article-title":"Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations","volume":"125","author":"Pawlyn","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.10.001_bib0088","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1365-2141.2006.06481.x","article-title":"Abnormalities of chromosome 1p\/q are highly associated with chromosome 13\/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma","volume":"136","author":"Wu","year":"2007","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.10.001_bib0089","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.bbmt.2009.11.025","article-title":"Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy","volume":"16","author":"Nemec","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"16","key":"10.1053\/j.seminhematol.2024.10.001_bib0090","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1002\/cncr.34895","article-title":"Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma","volume":"129","author":"Mohan","year":"2023","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2024.10.001_bib0091","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/787809","article-title":"Extramedullary manifestation in multiple myeloma bears high incidence of poor cytogenetic aberration and novel agents resistance","volume":"2015","author":"Qu","year":"2015","journal-title":"Biomed Res Int"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.10.001_bib0092","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/ajh.23705","article-title":"Patients with newly diagnosed multiple myeloma and chromosome 1 amplification have poor outcomes despite the use of novel triplet regimens","volume":"89","author":"Biran","year":"2014","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.10.001_bib0093","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1038\/sj.leu.2404403","article-title":"Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma","volume":"20","author":"Fonseca","year":"2006","journal-title":"Leukemia"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.10.001_bib0094","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.3324\/haematol.2009.016436","article-title":"Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation","volume":"95","author":"Neben","year":"2010","journal-title":"Haematologica"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.10.001_bib0095","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.3109\/10428194.2012.684349","article-title":"1q21 amplification with additional genetic abnormalities but not isolated 1q21 gain is a negative prognostic factor in newly diagnosed patients with multiple myeloma treated with thalidomide-based regimens","volume":"53","author":"Grzasko","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"15","key":"10.1053\/j.seminhematol.2024.10.001_bib0096","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1182\/bloodadvances.2020002218","article-title":"Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities","volume":"4","author":"Abdallah","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.10.001_bib0097","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/leu.2017.179","article-title":"Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients","volume":"32","author":"Shah","year":"2018","journal-title":"Leukemia"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.10.001_bib0098","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1182\/bloodadvances.2019001425","article-title":"Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents","volume":"4","author":"Giri","year":"2020","journal-title":"Blood Adv"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.10.001_bib0099","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.3324\/haematol.2014.103853","article-title":"Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies","volume":"99","author":"Caltagirone","year":"2014","journal-title":"Haematologica"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.10.001_bib0100","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/ajh.26639","article-title":"Chromosome 1q21 aberrations identify ultra high-risk myeloma with prognostic and clinical implications","volume":"97","author":"Kastritis","year":"2022","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.10.001_bib0101","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.3324\/haematol.2015.136929","article-title":"Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma","volume":"101","author":"Weinhold","year":"2016","journal-title":"Haematologica"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.10.001_bib0102","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/ajh.26774","article-title":"Proposed risk-scoring model for estimating the prognostic impact of 1q gain in patients with newly diagnosed multiple myeloma","volume":"98","author":"Yang","year":"2023","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.10.001_bib0103","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/hon.2018","article-title":"Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients","volume":"31","author":"Grzasko","year":"2013","journal-title":"Hematol Oncol"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.10.001_bib0104","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/j.bbmt.2016.07.007","article-title":"Post-transplant outcomes in high-risk compared with non-high-risk multiple myeloma: a CIBMTR analysis","volume":"22","author":"Scott","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.10.001_bib0105","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41408-023-00973-w","article-title":"Outcomes of patients with multiple myeloma and 1q gain\/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience","volume":"14","author":"Pasvolsky","year":"2024","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.10.001_bib0106","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41408-022-00611-x","article-title":"A simple additive staging system for newly diagnosed multiple myeloma","volume":"12","author":"Abdallah","year":"2022","journal-title":"Blood Cancer J"},{"issue":"19","key":"10.1053\/j.seminhematol.2024.10.001_bib0107","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1200\/JCO.18.00776","article-title":"Development and validation of a cytogenetic prognostic index predicting survival in multiple myeloma","volume":"37","author":"Perrot","year":"2019","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.10.001_bib0108","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-019-0254-0","article-title":"Gain of chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone","volume":"9","author":"Schmidt","year":"2019","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.10.001_bib0109","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/ejh.12546","article-title":"Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21","volume":"96","author":"Nahi","year":"2016","journal-title":"Eur J Haematol"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.10.001_bib0110","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.bbmt.2016.09.003","article-title":"Outcome of patients with multiple myeloma and CKS1B gene amplification after autologous hematopoietic stem cell transplantation","volume":"22","author":"Bock","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.10.001_bib0111","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.bbmt.2019.12.726","article-title":"Outcome of multiple myeloma with chromosome 1q gain and 1p deletion after autologous hematopoietic stem cell transplantation: propensity score matched analysis","volume":"26","author":"Varma","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.10.001_bib0112","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1080\/10428194.2016.1260126","article-title":"Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation","volume":"58","author":"Shah","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.10.001_bib0113","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1365-2141.2006.06325.x","article-title":"Multiple myeloma patients with CKS1B gene amplification have a shorter progression-free survival post-autologous stem cell transplantation","volume":"135","author":"Chang","year":"2006","journal-title":"Br J Haematol"},{"issue":"21","key":"10.1053\/j.seminhematol.2024.10.001_bib0114","doi-asserted-by":"crossref","first-page":"7819","DOI":"10.1002\/cam4.3254","article-title":"Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: a multicenter study in China","volume":"9","author":"Gao","year":"2020","journal-title":"Cancer Med"},{"issue":"14","key":"10.1053\/j.seminhematol.2024.10.001_bib0115","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1182\/blood.2022018339","article-title":"Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the myeloma XI trial","volume":"141","author":"Panopoulou","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.10.001_bib0116","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/bjh.16292","article-title":"Daratumumab in high-risk relapsed\/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain\/amplification and GEP70 status on outcome","volume":"189","author":"Mohan","year":"2020","journal-title":"Br J Haematol"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.10.001_bib0117","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1182\/blood-2023-173494","article-title":"Multiple myeloma with 1q gain\/amplification shows reduced CD38 expression via IL-6R overexpression","volume":"142","author":"Kuroki","year":"2023","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.10.001_bib0118","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.3324\/haematol.2022.280660","article-title":"Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed\/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA","volume":"107","author":"Martin","year":"2022","journal-title":"Haematologica"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.10.001_bib0119","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/14712598.2024.2357382","article-title":"Anti-CD38 monoclonal antibodies in multiple myeloma with gain\/amplification of chromosome arm 1q: a review of the literature","volume":"24","author":"Barbieri","year":"2024","journal-title":"Expert Opin Biol Ther"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.10.001_bib0120","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.10.001_bib0121","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41408-020-00357-4","article-title":"Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study","volume":"10","author":"Dimopoulos","year":"2020","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.10.001_bib0122","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/S2352-3026(20)30354-9","article-title":"Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial","volume":"8","author":"Usmani","year":"2021","journal-title":"Lancet Haematol"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.10.001_bib0123","doi-asserted-by":"crossref","first-page":"7297","DOI":"10.1182\/blood-2022-163494","article-title":"Daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in transplant-ineligible patients (Pts) with newly diagnosed multiple myeloma (NDMM): clinical assessment of key subgroups of the phase 3 maia study","volume":"140","author":"Moreau","year":"2022","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.10.001_bib0124","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","article-title":"Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial","volume":"10","author":"Voorhees","year":"2023","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.10.001_bib0125","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41408-024-01088-6","article-title":"Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN","volume":"14","author":"Chari","year":"2024","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.10.001_bib0126","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003454","article-title":"Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial","volume":"18","author":"Jackson","year":"2021","journal-title":"PLoS Med"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.10.001_bib0127","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1002\/ajh.26261","article-title":"Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by cytogenetic risk","volume":"96","author":"Richard","year":"2021","journal-title":"Am J Hematol"},{"issue":"20","key":"10.1053\/j.seminhematol.2024.10.001_bib0128","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1182\/blood.2023023597","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma","volume":"143","author":"Touzeau","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.10.001_bib0129","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1200\/JCO.23.01696","article-title":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma","volume":"42","author":"Leypoldt","year":"2023","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1053\/j.seminhematol.2024.10.001_bib0130","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1200\/JCO.22.02567","article-title":"Daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone as induction and extended consolidation improves outcome in ultra-high-risk multiple myeloma","volume":"41","author":"Kaiser","year":"2023","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.10.001_bib0131","doi-asserted-by":"crossref","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","volume":"9","author":"Goldschmidt","year":"2022","journal-title":"Lancet Haematol"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.10.001_bib0132","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2023-177546","article-title":"Results of the phase III randomized Iskia trial: isatuximab-carfilzomib-lenalidomide-dexamethasone vs carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma patients","volume":"142","author":"Gay","year":"2023","journal-title":"Blood"},{"issue":"10292","key":"10.1053\/j.seminhematol.2024.10.001_bib0133","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial","volume":"397","author":"Moreau","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.10.001_bib0134","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1470-2045(22)00019-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study","volume":"23","author":"Richardson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.10.001_bib0135","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S1470-2045(20)30452-6","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"issue":"Supplement 2","key":"10.1053\/j.seminhematol.2024.10.001_bib0136","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/S2152-2650(21)02126-1","article-title":"OAB-052: Impact of chromosome 1 abnormalities on newly diagnosed multiple myeloma treated with proteasome inhibitor, immunomodulatory drug, and dexamethasone: analysis from the ENDURANCE ECOG-ACRIN E1A11 trial","volume":"21","author":"Kapoor","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.10.001_bib0137","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-024-01075-x","article-title":"Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells","volume":"14","author":"D'Agostino","year":"2024","journal-title":"Blood Cancer J"},{"issue":"15_suppl","key":"10.1053\/j.seminhematol.2024.10.001_bib0138","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.1200\/JCO.2021.39.15_suppl.8002","article-title":"Carfilzomib-based induction\/consolidation with or without autologous transplant (ASCT) followed by lenalidomide (R) or carfilzomib-lenalidomide (KR) maintenance: efficacy in high-risk patients","volume":"39","author":"Gay","year":"2021","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.10.001_bib0139","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","volume":"22","author":"Gay","year":"2021","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.10.001_bib0140","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ccr.2006.08.027","article-title":"The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak\/Bax if Mcl-1 is neutralized","volume":"10","author":"van Delft","year":"2006","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.10.001_bib0141","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2011-01-327197","article-title":"Distribution of BIM determines Mcl-1 dependence or codependence with Bcl-xL\/Bcl-2 in Mcl-1-expressing myeloma cells","volume":"118","author":"Morales","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.10.001_bib0142","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.1038\/s41467-018-07551-w","article-title":"Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia","volume":"9","author":"Tron","year":"2018","journal-title":"Nat Commun"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.10.001_bib0143","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1038\/s41375-019-0421-0","article-title":"BCL2 blockade overcomes MCL1 resistance in multiple myeloma","volume":"33","author":"Siu","year":"2019","journal-title":"Leukemia"},{"issue":"16_Supplement","key":"10.1053\/j.seminhematol.2024.10.001_bib0144","doi-asserted-by":"crossref","first-page":"6218","DOI":"10.1158\/1538-7445.AM2020-6218","article-title":"Abstract 6218: Discovery and preclinical evaluation of AMG 397, a potent, selective and orally bioavailable MCL1 inhibitor","volume":"80","author":"Caenepeel","year":"2020","journal-title":"Cancer Res"},{"issue":"7626","key":"10.1053\/j.seminhematol.2024.10.001_bib0145","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature19830","article-title":"The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models","volume":"538","author":"Kotschy","year":"2016","journal-title":"Nature"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.10.001_bib0146","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.3324\/haematol.2018.212308","article-title":"Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma","volume":"105","author":"Algar\u00edn","year":"2020","journal-title":"Haematologica"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.10.001_bib0147","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1158\/2159-8290.CD-18-0387","article-title":"AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies","volume":"8","author":"Caenepeel","year":"2018","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.10.001_bib0148","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101015","article-title":"MCL-1 inhibition by selective BH3 mimetics disrupts mitochondrial dynamics causing loss of viability and functionality of human cardiomyocytes","volume":"23","author":"Rasmussen","year":"2020","journal-title":"iScience"},{"issue":"S3","key":"10.1053\/j.seminhematol.2024.10.001_bib0149","doi-asserted-by":"crossref","first-page":"e98838e7","DOI":"10.1097\/01.HS9.0000969220.98838.e7","article-title":"P579: safety, tolerability, pharmacokinetics, and preliminary antitumor activity of AZD5991 in relapsed\/refractory hematologic malignancies: a phase 1 first-in-human study","volume":"7","author":"Desai","year":"2023","journal-title":"Hemasphere"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.10.001_bib0150","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s43856-023-00380-z","article-title":"Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients","volume":"3","author":"Yuda","year":"2023","journal-title":"Commun Med (Lond)"},{"issue":"8_Supplement","key":"10.1053\/j.seminhematol.2024.10.001_bib0151","doi-asserted-by":"crossref","first-page":"CT172","DOI":"10.1158\/1538-7445.AM2023-CT172","article-title":"Abstract CT172: a phase 1, open-label, dose-escalation study of PRT1419, a selective induced myeloid leukemia cell differentiation protein (MCL-1) inhibitor, in patients (pts) with advanced\/metastatic solid tumors","volume":"83","author":"Falchook","year":"2023","journal-title":"Cancer Res"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.10.001_bib0152","article-title":"Systematic characterization of therapeutic vulnerabilities in multiple myeloma with Amp1q reveals increased sensitivity to the combination of MCL1 and PI3K inhibitors","volume":"8","author":"Sklavenitis-Pistofidis","year":"2023","journal-title":"bioRxiv [Preprint]"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.10.001_bib0153","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ccell.2017.02.001","article-title":"Membrane-proximal epitope facilitates efficient T cell synapse formation by anti-FcRH5\/CD3 and is a requirement for myeloma cell killing","volume":"31","author":"Li","year":"2017","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.10.001_bib0154","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.1038\/s41467-023-39395-4","article-title":"Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma","volume":"14","author":"Jiang","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.10.001_bib0155","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41392-023-01702-2","article-title":"Fc receptor-like 5 (FCRL5)-directed CAR-T cells exhibit antitumor activity against multiple myeloma","volume":"9","author":"Yu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"16_suppl","key":"10.1053\/j.seminhematol.2024.10.001_bib0156","doi-asserted-by":"crossref","first-page":"TPS8064","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8064","article-title":"CAMMA 2: a phase I\/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed\/refractory multiple myeloma (RRMM) who have triple-class refractory disease and have received a prior anti-B-cell maturation antigen (BCMA) agent","volume":"41","author":"Kumar","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.10.001_bib0157","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1172\/JCI85856","article-title":"Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells","volume":"126","author":"Sherbenou","year":"2016","journal-title":"J Clin Invest"},{"issue":"Supplement 2","key":"10.1053\/j.seminhematol.2024.10.001_bib0158","doi-asserted-by":"crossref","first-page":"S164","DOI":"10.1016\/S2152-2650(21)02352-1","article-title":"P-225: a first-in-human study of FOR46 in patients with triple refractory multiple myeloma","volume":"21","author":"Wong","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.10.001_bib0159","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","article-title":"A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis","volume":"33","author":"Walker","year":"2019","journal-title":"Leukemia"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.10.001_bib0160","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1002\/ajh.25994","article-title":"The prognostic value of additional copies of 1q21 in multiple myeloma depends on the primary genetic event","volume":"95","author":"Locher","year":"2020","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.10.001_bib0161","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.3324\/haematol.2021.278888","article-title":"Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients","volume":"106","author":"Weinhold","year":"2021","journal-title":"Haematologica"},{"issue":"33","key":"10.1053\/j.seminhematol.2024.10.001_bib0162","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1200\/JCO.2014.59.1503","article-title":"Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma","volume":"33","author":"Walker","year":"2015","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.10.001_bib0163","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.3324\/haematol.2011.056176","article-title":"Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders","volume":"97","author":"Ross","year":"2012","journal-title":"Haematologica"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.10.001_bib0164","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/cncr.34641","article-title":"The prognostic role of 1q21 gain\/amplification in newly diagnosed multiple myeloma: the faster, the worse","volume":"129","author":"Wang","year":"2023","journal-title":"Cancer"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.10.001_bib0165","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1158\/1078-0432.CCR-14-2576","article-title":"The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma","volume":"21","author":"An","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.10.001_bib0166","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.clml.2022.01.013","article-title":"The importance of FISH signal cut-off value and copy number variation for 1q21 in newly diagnosed multiple myeloma: is it underestimated?","volume":"22","author":"Gao","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.10.001_bib0167","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00277-021-04704-8","article-title":"Outcomes of patients with multiple myeloma harboring chromosome 1q gain\/amplification in the era of modern therapy","volume":"101","author":"Hu","year":"2022","journal-title":"Ann Hematol"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324001112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324001112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T14:07:58Z","timestamp":1741961278000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196324001112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":167,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0037196324001112"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.10.001","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of 1q abnormalities in multiple myeloma: Genomic insights, clinical implications, and therapeutic challenges","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}